GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids. Moreover, while the absence of acute GvHD (aGvHD) is associated with a higher risk of relapse of the underlying malignant disease, severe aGvHD usually induces the occurrence of life-threatening complications such as severe infections. This article summarizes the current state of aGvHD prophylaxis and treatment.
Prevention
Although the prognosis of acute GvHD (aGvHD) has dramatically improved in the last few years, morbidity and mortality from aGvHD remain the main cause of unsuccessful allogeneic haematopoietic SCT (HSCT).
Clinical factors that may influence the development of GvHD are related to donor-host factors, source of stem cells and types of preparative regimens given before transplant. Among donor-host variables, the most commonly recognized GvHD risk factors are HLA differences, female donor to male recipient, and donor and recipient age. Moreover, a sterile environment is mandatory to protect against GvHD. 1 Unfortunately, in Italy, finding a matched related donor is becoming increasingly more difficult, while there is a greater use of alternative donors or mismatched relatives. The source of HSCT may also influence the incidence of GvHD. As a matter of fact, BM, PBSC and cord blood have little impact on aGvHD, while the incidence of chronic GvHD (cGvHD) significantly increases after PBSC. [2] [3] [4] Low incidence of both aGvHD and cGvHD was observed in adults and in children after related or unrelated cord blood infusion. [5] [6] [7] The use of intensive conditioning regimens and, in particular, of high doses of TBI induces a greater risk of GvHD because it increases the tissue damage, which represents the first phase of the pathophysiology of aGvHD.
Removing T cells from the graft, that is, T-cell depletion (TCD) ex vivo was very effective in preventing GvHD, but survival, disease-free survival and TRM rates did not decrease as compared to conventional, unmanipulated graft. 8 Conversely, in the setting of three Ag-mismatched transplants, TCD proved to be essential. 9 Moreover, the number of infused T cells should not exceed 5 Â 10 4 cells per kg of recipient body weight. 9 Furthermore, adding T-cell Abs to the conventional conditioning regimen (TCD in vivo) has a two-fold effect: it reduces the host response, thus improving engraftment, and affects mature donor T cells in the graft due to the long half-life of the Abs. [10] [11] [12] TCD in vivo is obtained by many strategies and, in particular, by those involving alternative donors using agents such as alemtuzemab (Campath) or anti-thymocyte globulin (ATG). In a recent trial involving adult patients, ATG significantly reduced grades II-IV aGvHD in unrelated donors without increasing TRM. 13 Bacigalupo et al. 14 demonstrated that ATG provides protection against aGvHD and cGvHD, shortens the duration of immunosuppressive therapy, and improves the quality of life. Careful, prolonged monitoring of patients should be carried out since the incidence of viral and fungal infections is higher and immune reconstitution is delayed in recipients who receive ATG. 13 A paediatric study is currently ongoing to determine whether different schedules of ATG administration may improve outcome on the basis of donor-recipient matching.
Over the last few years, great attention has been focused on the potential of regulatory T cells (Tregs) for suppressing alloreactivity in the setting of allogeneic transplantation in mice. Naturally arising CD4 þ CD25 þ Tregs have the potential to suppress aberrant immune responses and to regulate peripheral T-cell homoeostasis. The higher frequency of CD4 þ CD25 þ in the peripheral blood of allotransplant recipients correlates with greater frequency of cGvHD. Tregs inhibit the division, expansion and differentiation of donor T cells specific for host Ags. Recently, preclinical studies have shown that the same amount of Tregs and of donor T cells must be infused to prevent GvHD. 15 Thus, expanding Tregs ex vivo prior to transplantation would be mandatory. The latter allow for control of GvHD without decreasing the graft versus leukaemia effect and facilitate immunoreconstitution. How these findings may be adopted in the human setting is yet to be established.
Immunosuppressive therapy for the prevention of aGvHD is based on mechanisms that interfere with T-cell activation and function. CsA is a calcineurin inhibitor and it is considered the most important drug currently being used in the prevention of GvHD, since it acts by inhibiting T-cell proliferation and IL-2 production. The main side effects include hypertension, nephrotoxicity, neurotoxicity and liver cholestasis. The standard prophylaxis protocol used in adult patients consists of a combined 'short' MTX regimen given on days þ 1, þ 3, þ 6 and þ 11 associated with CsA given c.i. at a dosage of 3 mg/kg/day and followed by oral treatment for as long as GvHD persists or until day þ 180 in case of GvHD absence. Adding steroids has not been found to confer any beneficial effects. [16] [17] [18] Two different prospective trials in adults and children showed that low-dose CsA (1 mg/kg) has a significant impact on leukaemia recurrence when compared with higher doses (3-5 mg/kg). 19, 20 These results were updated for adults and are important for patients with high-risk leukaemia. Improved results in adults were obtained by using 1 mg/kg CsA from day À7 combined with 'short MTX' in the unrelated donor setting. 19 The efficacy of this approach in children is currently under investigation.
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Tacrolimus (FK506) is a macrolide that inhibits the phosphorylase activity of calcineurin, and this mechanism induces the inhibition of the IL-2 gene expression. Recently, a prospective comparison was carried out between tacrolimus combined with 'short MTX' and conventional CsA/MTX in adult unrelated transplants. 22 The patients who received tacrolimus showed a significantly lower occurrence of aGvHD II-IV, though no changes in the incidence of cGvHD were observed. Side effects, leukaemia recurrence and overall survival were comparable in both arms. 22 Yanik et al. 23 described a group of paediatric recipients receiving GvHD prophylaxis with tacrolimus given at a dosage of 0.03 mg/kg/day by continuous infusion who were then switched to oral therapy. The most common adverse effects included hypomagnesaemia (98%), hypertension (49%), nephrotoxicity (34%), tremors (32%), seizures and hyperglycaemia (o10% cases). These authors concluded that tacrolimus is well tolerated in paediatric patients. A prospective randomized trial in paediatric patients comparing low-dose tacrolimus versus low-dose CsA in HLA identical siblings is currently ongoing.
Mycophenolate mofetil (MMF) was recently introduced for the prevention of GvHD and, in particular, to avoid problems associated with MTX such as increased time to haematopoietic engraftment, mucositis and other organ toxicities. MMF has been used successfully in association with CsA for GvHD prophylaxis in non-myeloablative transplantation and may replace MTX on account of the occurrence of fewer cases of mucositis and good tolerability. 24 New hope has arisen due to MSCs for the prevention of GvHD. MSCs are pluripotent stem cells that are able to differentiate into different types of tissue such as osteoblasts, myoblasts, adipocytes and stromal cells. 25 Their immunosuppressive effects have been shown in vitro and in vivo. 25, 26 Co-infusion of MSCs with unmanipulated BM or PBSC in the HLA-identical setting was safe, and early haematopoietic reconstitution was observed. 27 Unfortunately, this study was unable to demonstrate a decrease in the number of cases of aGvHD and cGvHD. It is noteworthy that the number of MSCs infused in animal models is 3 logs higher than that infused in the human setting, 27 and thus we may need to increase the number of MSCs in humans to achieve the same results. Moreover, it is important to note, as shown elsewhere, that MSCs are immunoprivileged and display immunosuppressive activity under defined conditions. The immunomodulatory properties of MSCs in murine models of allogeneic transplantation were investigated. Adding host MSCs into sublethally irradiated recipients who received allogeneic HSCT significantly enhanced long-term engraftment associated with tolerance to host and donor Ags. However, the infusion of donor MSCs was associated with significantly increased rejection of allogeneic donor BM.
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Host APCs also seem to play a pivotal role in GvHD development, and thus decreased activity of host APC may reduce GvHD. Extracorporeal photopheresis (ECP) is pheresis of approximately 5 Â 10 9 leukocytes that are treated with a photoactivable compound (8-methoxypsoralen) and ultraviolet A light and returned to the patients. This therapy induces apoptosis in all treated leukocytes. The infused apoptotic cells are taken up by host APC, thereby triggering certain tolerance mechanisms, and thus are of therapeutic use in GvHD. 29, 30 Accordingly, patients receiving ECP prior to the conditioning regimen have a lower incidence of GvHD. 31 Moreover, donor-incompatible natural killer cells are able to kill host APC in mice, preventing GvHD. 32 Aversa et al. 33 showed that co-infusion of expanded incompatible donor natural killer cells reduces GvHD by killing the host APC and may also have an antitumour effect on leukaemia cells by killing them.
Reduced intensity conditioning regimens were introduced for children with malignant and non-malignant diseases. 34 In 2005, the European Group for Blood and Marrow Transplantation definitions committee defined reduced intensity conditioning as a conditioning regimen in which the dosage of chemotherapy and/or TBI was reduced to 50% or less of the standard regimen, or a single drug was given at 100% of the standard dose but without other drugs. These regimens may be associated with less toxicity and less severe aGvHD due to the persistence of host cells (mixed chimaeras) and to a lower level of inflammatory cytokines. 35 Nonetheless, aGvHD (grades III-IV) still occurs in 15% of patients, as does cGVHD in 50% of survivors. Several questions still have to be answered in this context, that is, the timing and intensity of immunosuppression, timing and number of donor lymphocyte infusion, and utilization of T-cell Abs such as ATG or alentuzumab. 34, 35 Recently, a conditioning regimen based on TLI plus ATG was found to protect mice against GvHD after HSCT. 36 Potent antitumour effects were also observed in patients with malignant lymphoid diseases who achieved PR after being administered TLI and ATG prior to an infusion of HLA-related or unrelated mobilized PBSC.
In preclinical studies, protection against GvHD was found to depend on host natural killer T cells that were the main source of host IL-4. Various MoAbs (anti-IL-2; antitumour necrosis factor (TNF) and anti-CD25) were administered in an attempt to prevent GvHD; however, no real benefits were observed. [37] [38] [39] Using these different types of prophylaxis over the last 10 years, we have observed a progressive decrease in severe forms of aGvHD, thus leading to lower mortality and morbidity. However, whether the decrease in GvHD actually induces an increase in survival is yet to be seen.
Treatment
First-line treatment Steroids associated with CsA or tacrolimus are usually considered standard therapy for the first-line treatment of aGvHD. Different types and dosages of steroids are used in the initial management of aGvHD, but methylprednisolone (6MPD) given at a dosage of 2 mg/kg/day is more frequently administered. The efficacy of steroids in curing aGvHD, in improving the outcome and in increasing the probability of survival is acknowledged. Moreover, several side effects, such as hyperglycaemia, osteoporosis and growth defects, represent the main limitations to long-term use. Blazar 40 concluded that steroids were inadequate in severe forms of aGvHD and that more effective prophylaxis is needed for non-identical transplants or alternative donors. The Group for Marrow Transplantation has carried out prospective studies to identify the best strategy for the treatment of aGvHD. [41] [42] [43] The conclusions of these studies are the following: more aggressive first line therapy is not beneficial. In particular, there were no differences in terms of TRM between high doses (10 mg/kg/day) versus low doses (2 mg/kg/day) of 6MPD, or between patients treated with ATG versus patients who received average doses (5 mg/kg/day) of 6MPD. Moreover, the Group for Marrow Transplantation study showed that high dose 6MPD did not prevent the progression of aGvHD and that patients who showed early response to low doses of steroids had significantly lower TRM, while the non-early responders were eligible for alternative immunosuppressive therapies.
Second-line treatment
By conventional definition, we say that aGvHD is not responsive to steroids under the following conditions: when there is a progression of aGvHD after 3 days of steroid administration; when there are no clinical or biochemical changes after 7 days; or when there is incomplete response after 14 days of steroid treatment. These patients require secondary salvage treatment. 44, 45 Switching from CsA to FK506 proved to be beneficial for 12% of patients. 46 ATG was another option for steroid-resistant patients. Unfortunately, a prospective randomized Group for Marrow Transplantation study showed no difference between patients who were randomized to receive 2 mg/kg of 6MPD for 10 days alone and those who were administered 6MPD associated with rabbit ATG. 43 In fact, although ATG can control GvHD, some responders died of infections and other complications. Among the group of MoAbs, the anti-CD25 MoAb (daclizumab) provides competitive inhibition of the binding of IL-2 to its receptor. Complete response was reported in 47% of patients treated with daclizumab at a dosage of 1 mg/kg/day for each dose. Infections and GvHD recurrence represented the main causes of death in these recipients. 47 Other IL-2 receptor Abs include basiliximab, denileukin diftitox and hybrid toxin. 44 TNF Abs or anti-TNF receptors are usually used to cure autoimmune diseases, but in the setting of steroid-resistant aGvHD they represent a possible therapeutic strategy. 48, 49 Infliximab blocks the interaction between TNF-a and its receptors and causes lysis of the cells that produce TNF-a. Some response has been observed following TNF-a administration, but infections are still a big problem.
An anti-CD147 murine MoAb (a neurothelin member of the Ig superfamily that is upregulated on activated B and T cells) induced 50% (25% CR) response in steroid-resistant aGvHD. Moderate to severe myalgia occurred in 28-60% of cases and was dose limiting. 50 Visilizumab is a humanized anti-CD3 Ab that selectively induces apoptosis of activated T cells. A phase I study demonstrated that all patients affected by severe aGvHD and treated with visilizumab improved and that 37% of them achieved CR. 51 Pentostatin inhibits adenosine deaminase. Jacobsohn and Vogelsang 52 reported an overall response in up to 67% of patients treated with pentostatin.
Sirolimus (rapamycin) is a macrolide from streptomyces, which seems to have some beneficial effects, and it has dose-limiting toxicity represented by marrow hypoplasia. 53, 54 MMF may also have some beneficial effects. The major side effects reported in patients treated with MMF are neutropaenia and gut ulcerations.
Cell therapy for steroid-resistant aGvHD includes the use of MSCs, 54, 55 suicide gene transduction of T cells and ECP. A cooperative study regarding the use of MSCs as a therapy for GvHD and involving three centres was recently presented at the European Group for Blood and Marrow Transplantation 2006 meeting. Among 40 patients who received MSCs (at a median dose of 1 Â 10 6 cells per kg body weight of recipient) for aGvHD, 47.5% had CR. No side effects were observed. These results need to be confirmed in large prospective trials, especially keeping in mind that contradictory results have been reported in preclinical studies.
Another approach is the one based on transducing T cells with a gene 1 that makes them susceptible to killing by ganciclovir. Considering the complex technique requiring efficient gene transduction and the ability to select transduced cells, this approach is presently not being used as a standard approach; however, it represents an interesting study tool.
ECP has been proposed as a therapy for resistant aGvHD, and it has been seen that patients responding to ECP have a significantly better outcome than nonresponders. [56] [57] [58] [59] A multi-centre paediatric study 58 showed that ECP is an effective treatment modality for paediatric patients with refractory GvHD. 54 The authors observed an improvement in GvHD in the 77 children who were treated with ECP for aGvHD (n ¼ 33) or cGvHD (n ¼ 44) and were resistant to conventional immunosuppressive therapy. In particular, skin aGvHD responded to ECP in 76% of patients, followed by gut aGvHD (75%) and liver aGvHD (60%). The 5-year overall survival was 69% for responding patients versus 12% for non-responders (P ¼ 0.001). Among the patients affected by cGvHD, 34% achieved CR, while 23% showed significant improvement after ECP. The 5-year overall survival rate was 96% for responders versus 58% for nonresponders (P ¼ 0.04). The authors concluded that ECP represents an effective treatment modality that may be useful in paediatric patients with either aGvHD or cGvHD who fail to respond to standard immunosuppressive therapy.
The mechanisms and main side effects of the agents used in steroid-resistant aGvHD are reported in Table 1 .
Conclusion
In conclusion, 50% of patients with aGvHD can be treated with first-line treatment, but if it is resistant to corticosteroids, prognosis becomes dismal. New drugs, new Abs or increased immunosuppression, and immunomodulatory procedures such as ECP may induce remission of GvHD, but problems involving infections or side effects still exist. Cellular therapy seems promising, as does the possibility of inducing immunotolerance. 
